Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (UTHR) is a pioneering biotechnology company dedicated to developing and commercializing innovative products that address unmet medical needs for patients with chronic and life-threatening conditions. The company's core business revolves around the creation of treatments for pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by high blood pressure in the lungs' arteries. United Therapeutics' therapies predominantly focus on the prostacyclin pathway, with many treatments based on the molecule treprostinil.
With five approved products on the market, United Therapeutics is relentless in its mission to deliver 'medicines for life.' The company's long-term vision includes providing an unlimited supply of transplantable organs to those in need. Employees collaborate across the United States, Europe, and Asia to achieve this ambitious goal.
In addition to its focus on PAH, the company is also dedicated to researching and developing treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. United Therapeutics markets a pediatric oncology drug, but its primary focus remains on advancing therapeutics for PAH.
United Therapeutics has seen significant achievements in recent years, continually pushing the boundaries of medical science. Their financial condition remains robust, driven largely by sales within the United States. The company is actively engaged in various partnerships and projects aimed at enhancing their therapeutic offerings and expanding their global footprint.
United Therapeutics Corporation (Nasdaq: UTHR) announced that the FDA has granted orphan drug designation to treprostinil for treating idiopathic pulmonary fibrosis (IPF). The company plans to initiate a phase 3 study named TETON to evaluate Tyvaso (treprostinil) Inhalation Solution in IPF patients, with enrollment expected in 2021. This designation provides potential benefits like seven years of market exclusivity post-approval and may extend to the Treprostinil Technosphere upon approval. IPF affects around 100,000 individuals in the U.S. annually.
United Therapeutics Corporation (Nasdaq: UTHR) released its inaugural Corporate Responsibility Report, highlighting 2019 data and selected 2020 updates. This report outlines the company’s commitment to environmental, social, and governance (ESG) priorities, developed with guidance from its Board of Directors and based on GRI and SASB metrics. CEO Martine Rothblatt emphasized the company's long-standing focus on corporate responsibility. United Therapeutics plans to continue these reports annually, with the next expected around mid-2021.
United Therapeutics Corporation (Nasdaq: UTHR) announced that CFO James Edgemond will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, from 6:45 to 7:15 p.m. GMT. The live webcast will be available on their website, with an archived version accessible for 90 days post-event. United Therapeutics emphasizes innovation and quality in their biotechnology model and addresses organ shortages through their subsidiary, Lung Biotechnology PBC.
United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will present at the Credit Suisse 29th Annual Virtual Healthcare Conference. The presentation is scheduled for November 9, 2020, from 2:45 to 3:25 p.m. EST, and will be accessible via a live webcast on the company's website. An archived version will be available 24 hours post-event for 90 days. United Therapeutics focuses on innovation and sustainability in biotechnology, particularly through its subsidiary Lung Biotechnology PBC, which addresses the shortage of transplantable organs.
United Therapeutics (Nasdaq: UTHR) reported Q3 2020 revenues of $380.1 million, down 5% from $401.5 million in Q3 2019. Despite this decline, net income rose by 29% to $171.2 million, translating to $3.86 per basic share. The company anticipates revenue growth from upcoming product launches, including Tyvaso's label expansion and the introduction of the Remunity Pump. Year-over-year, sales for Tyvaso and Orenitram increased by 17% and 20%, respectively, while Remodulin revenues fell by 26% due to competition and a distributor order issue.
United Therapeutics Corporation (Nasdaq: UTHR) presented new clinical data on Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the CHEST 2020 conference. The phase 3 INCREASE study showed that patients receiving Tyvaso experienced fewer exacerbations of lung disease and improvements in forced vital capacity (FVC) compared to placebo. With an estimated 30,000 PH-ILD patients in the U.S. and no current FDA-approved therapies, the data underscore Tyvaso's potential in addressing this serious condition.
United Therapeutics Corporation (Nasdaq: UTHR) announced it will report its third quarter 2020 financial results on October 28, 2020, before market opens. A teleconference will follow at 9:00 a.m. ET, accessible via phone and webcast on their website. The company emphasizes a commitment to innovation and quality, alongside efforts to address the shortage of transplantable organs through its subsidiary, Lung Biotechnology PBC. They caution that forward-looking statements may be subject to risks that could cause actual results to differ.
United Therapeutics Corporation (Nasdaq: UTHR) announced its presentation of clinical trial data on Tyvaso® (treprostinil) at CHEST 2020, scheduled from October 18-21. This will include results from the phase 3 INCREASE study focusing on pulmonary hypertension associated with interstitial lung disease (PH-ILD). Other topics include data on the Orenitram® ADAPT registry and the psychological impact of pulmonary arterial hypertension (PAH). Key presenters include Aaron Waxman and John Kingrey. The e-posters will be available on the CHEST 2020 website.
United Therapeutics Corporation (Nasdaq: UTHR) will have its CEO, Dr. Martine Rothblatt, present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020. The session will run from 11:40 a.m. to 12:20 p.m. EDT and will be accessible via a live webcast on the company's website. An archived version will be available 24 hours post-session for 90 days. United Therapeutics is dedicated to innovation in biotechnology, focusing on organ transplant technologies through its subsidiary, Lung Biotechnology PBC, which aims to address organ shortages.
United Therapeutics Corporation (Nasdaq: UTHR) appointed Dr. Linda Maxwell as an independent director on September 10, 2020. Dr. Maxwell, a distinguished head and neck surgeon and healthcare innovator, brings extensive expertise in medical education and health technology entrepreneurship. She has held significant positions in various academic institutions and has experience managing startups in clinical development. United Therapeutics emphasizes the value of her achievements in advancing human health and innovative approaches in biotechnology.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
What does United Therapeutics Corporation specialize in?
How many approved products does United Therapeutics have?
What is pulmonary arterial hypertension?
What is the company's long-term mission?
Where are United Therapeutics' employees located?
What molecule forms the basis of many of the company's treatments?
Does United Therapeutics market any oncology drugs?
What drives United Therapeutics' financial condition?
Is United Therapeutics involved in partnerships?
What are the latest news and developments from United Therapeutics?
